Incyte Appoints Dr. Dashyant Dhanak as Chief Scientific Officer
November 27 2018 - 7:30AM
Business Wire
Incyte (NASDAQ:INCY) today announced the appointment of Dashyant
Dhanak, Ph.D. as Executive Vice President and Chief Scientific
Officer, effective December 10, 2018. Dr. Dhanak will succeed Dr.
Reid Huber, who has been at Incyte since 2002 and is leaving the
Company to pursue opportunities in the early-stage life sciences
community.
“Reid’s contributions to Incyte have been instrumental in its
evolution from a start-up operation to the world-class discovery
engine of today, and I thank him most sincerely for his commitment
and critical thinking over the last 16 years,” said Hervé Hoppenot,
Chief Executive Officer, Incyte. “Reid’s decision to pursue a
different career path has given us the opportunity to recruit a new
leader for our discovery team, and Dash brings an ideal mix of
discovery and development experience into what I believe is the
most innovative and productive group in the industry.”
Dr. Dhanak joins Incyte from Janssen Research & Development,
where he most recently served as Global Head, Discovery Sciences,
leading an organization responsible for supporting and enabling the
discovery and early development of novel therapeutics. Prior to
Janssen, Dr. Dhanak spent 25 years at GlaxoSmithKline.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based
biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics. For additional
information on Incyte, please visit the Company’s website at
www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181127005185/en/
MediaCatalina Loveman+1 302 498
6171cloveman@incyte.com
InvestorsMichael Booth, DPhil+1 302 498
5914mbooth@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Sep 2023 to Sep 2024